Access cutting-edge hereditary angioedema treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.
Access hereditary angioedema specialists in Cincinnati at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hereditary angioedema treatment provided free
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Sponsor: CSL Behring
Check if you qualify for this hereditary angioedema clinical trial in Cincinnati, OH
If you're searching for hereditary angioedema treatment options in Cincinnati, OH, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hereditary angioedema specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.